Tinnitus, Hyperacusis
Conditions
Interventions
None listed
Sponsors
Tohoku University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (A) Healthy hearing subjects (1) Healthy hearing subjects with no history of ear disease or neurological/neurological disease 2) Age: 20 years old or older, less than 40 years old (at the time of registration) (3) Gender: Any gender (B) Tinnitus patients (1) Patients with a tinnitus severity score (Tinnitus Handicap Inventory: THI) of 40 points or higher (THI is a tinnitus severity questionnaire routinely administered in the outpatient clinic (maximum score 100 points); a score of 40 or more is considered to indicate moderate or severe tinnitus requiring some form of therapeutic intervention.) (2) Age: 20 years old or older, less than 40 years old (3) Gender: Any gender. (C) Hyperacusis patients (1) Patients with a hearing sensitivity score (Hyperacusis Questionaire: HQ) of 28 points or higher (HQ is a questionnaire on the degree of distress of auditory sensitivity that is routinely administered in the outpatient clinic (maximum score 42 points). 28 points or more is considered as having a strong auditory sensitivity that requires some therapeutic intervention.) (2) Age: 20 years old or older, less than 40 years old (iii) Gender: Any gender.
Exclusion criteria
Exclusion criteria: (A) Hearing subjects 1) Those with a history of ear disease 2) Those with a history of mental illness 3) Those with a history of peripheral or central nervous system diseases 4) Those with a history of eye diseases (excluding myopia) 5) Those who are taking drugs that may affect the pupil system (antihistamines, decongestants, antidepressants, anti-vomiting agents, anticonvulsants, Parkinson drugs, etc.) 6) Those who are pregnant or may become pregnant 7) In addition, those who are judged by the principal investigator or coordinator to be inappropriate as subjects (B) Tinnitus patients, hyperacusis patients 1) Those with a history of eye diseases (excluding myopia) 2) Those who are taking drugs that may affect the pupil system (antihistamines, decongestants, antidepressants, anti-vomiting agents, anticonvulsants, Parkinson drugs, etc.) 3) Those who are pregnant or may become pregnant 4) In addition, those who are judged by the principal investigator or coordinator to be inappropriate as subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pupil diameter | — |
Countries
Japan
Contacts
Public ContactTetsuaki Kawase
Tohoku University Graduate School of Biomedical Engineering
Outcome results
None listed